Amphastar 
Welcome,         Profile    Billing    Logout  
 3 Products   20 Diseases  3 Products   1 Trial   108 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Baqsimi (glucagon intranasal dry powder) / Amphastar
RescuiNGkids, NCT04992312 / 2021-006088-61: A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

Completed
1
7
US
Glucagon Nasal Powder [Baqsimi], LY900018, Baqsimi
Eli Lilly and Company, Eli Lilly and Company
Type 1 Diabetes
11/23
11/23
2021-006088-61: A Study of Nasal Glucagon in Children with Insulin Dependent Diabetes

Not yet recruiting
1
6
US
Baqsimi (nasal glucagon), Nasal powder in single-dose container, Baqsimi
Eli Lilly and Company, Eli Lilly and Company
severe hypoglycemia, very low blood sugar, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
I004 (insulin aspart rapid-acting biosimilar) / Amphastar
NCT05539872: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Completed
2/3
69
US
I004, Insulin Aspart, a rapid-acting human insulin analogue, NovoLog
Amphastar Pharmaceuticals, Inc.
Pharmacokinetics, Pharmacodynamics
01/23
01/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Baqsimi (glucagon intranasal dry powder) / Amphastar
RescuiNGkids, NCT04992312 / 2021-006088-61: A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

Completed
1
7
US
Glucagon Nasal Powder [Baqsimi], LY900018, Baqsimi
Eli Lilly and Company, Eli Lilly and Company
Type 1 Diabetes
11/23
11/23
2021-006088-61: A Study of Nasal Glucagon in Children with Insulin Dependent Diabetes

Not yet recruiting
1
6
US
Baqsimi (nasal glucagon), Nasal powder in single-dose container, Baqsimi
Eli Lilly and Company, Eli Lilly and Company
severe hypoglycemia, very low blood sugar, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
I004 (insulin aspart rapid-acting biosimilar) / Amphastar
NCT05539872: Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Completed
2/3
69
US
I004, Insulin Aspart, a rapid-acting human insulin analogue, NovoLog
Amphastar Pharmaceuticals, Inc.
Pharmacokinetics, Pharmacodynamics
01/23
01/23

Download Options